Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Outstanding analysis.
Really good stuff!
Go for it!
Short away.
GLTY
The Company received notices of exercise of an aggregate $750,000 in purchase price
Peanuts
Agree
IDC predicts a “dramatic increase in the number of datacenters as cloud players race to achieve global scale.
Im back in.
Too many bullish divergences on charts to sit out.
Added today looking to add more in days to come.
GLTA
One of my fave stocks.
This is ultimately headed $10+ with ease.
IMO of course.
Im in at 2avg have been thinking we are headed higher to $3+ but market weakness will put a damper on rise without news imo. Someone has been accumulating recently imo but so much manipulation hard to tell?
Still cant believe how quiet it is here. This thing is starting to act like a huge runner.
Cant believe its so quiet here.
U.S. warns health officials to be alert for deadly new virus
The Centers for Disease Control and Prevention (CDC) on Thursday warned state and local health officials about potential infections from a deadly virus previously unseen in humans that has now sickened 14 people and killed 8.
Most of the infections have occurred in the Middle East, but a new analysis of three confirmed infections in Britain suggests the virus can pass from person to person rather than from animal to humans, the CDC said in its Weekly Morbidity and Mortality Report on Thursday.
The virus is a coronavirus, part of the same family of viruses as the common cold and the deadly outbreak of Severe Acute Respiratory Syndrome (SARS) that first emerged in Asia in 2003. The new virus is not the same as SARS, but like the SARS virus, it is similar to those found in bats.
So far, no cases have been reported in the United States.
http://ca.news.yahoo.com/u-warns-health-officials-alert-deadly-virus-230251928.html
Private Cloud is the future.
Secure data is critical.
The easier it is for entities to implement, the more prevelant it will be.
IWEB is at the forefront in this area.
TB Patient Nabbed On U.S. Border
In medical isolation in South Texas, 100 miles or so from Mexico's border, is a man who embodies one of U.S. health officials' greatest worries: He is the first person to cross and be held in detention while infected with one of the most severe types of drug-resistant tuberculosis known today
Tuberculosis, an ancient, fatal airborne disease, has been treatable for decades with a cocktail of drugs. However, shoddy medical practices world-wide have enabled the bacteria to mutate and, in some cases, become all but untreatable. In recent months The Wall Street Journal has exposed widening TB drug resistance in hot spots like India, and shown that the U.S. is surprisingly unprepared for the growing global problem.
http://online.wsj.com/article/SB10001424127887323978104578332461533970412.html?mod=WSJ_hpp_LEFTTopStories
And to think that this person came across our "secure" border with Mexico?
More proof America needs better bio-detection and bio-defense capabilities.
We also need to secure our borders.
I have worked closely with the Government as a liason to a multi-party partership performing signifant renovations to historic structures in a National Park
I do not trust Government timelines.
My comments are not meant to be critial, only to be more conservative.
Prediction of $6.00/$150.00(1/25) will only be achieved with awarding of final Gen 3 contract which will not happen in the near term(6-18 months).
What is possible in the near term (6-18 months)is company receives part of stage 1 contract and begins to develop enough bullish sentiment to drive stock back to 2 year highs of $1.09/$27.50(1-25).
I like the sound of a $27 stock with less than 14 Million shares outstanding on the verge of a possible Gen 3 contract.
That is a share structure more likely to achieve a $150 share price than where we sit now.
All IMO.
I agree.
I see this as a bullish development and do not think it would be enacted until/unless contract is awarded.
Once awarded portion of contract a R/S would be a good idea and could dramitacly change the dynamics of potential price appreciation.
It would also help to prevent a hostile buyout (by maintaining same # of available shares) as well as help facilitate a possible friendly sale of the company due to a more attractive share structure.
Small float, low dollar, low market cap companies with game changing tech. are best plays in the market.
All IMO of course.
A R/S enacted at the right time is bullish.
I agree with many comments that 9/10 times penny stocks conducting reverse splits it is a sign of desperation and is perceived negatively by shareholders. Many traders will sell any R/S announcement due to predictable patterns of declining market caps both before and immediately after an R/S takes place. In some cases the declines do not materialize however dependent upon the conditions present.
All that matters currently are contracts PSID is seeking (BioWatch / DTRA). It can be argued that a reverse split would be very helpful to PSID should they be awarded any significant portion of these contracts.
Here is my thesis (assume this was enacted today):
Current: pps = .02 / 52 week low = .011 / 52 week high = .14 / 2 year high = $1.09 (338 million shares outstanding)
1/25 split: pps = .50 / 52 week low = .28 / 52 week high = $3.48 / 2 year high = $27.25 (13.5 million shares outstanding)
Assume they are awarded at least a portion of the Stage 1 Gen 3 contract. I argue that this news would return the stock to 52 week highs and set the stage for potentially even higher prices and interest in the stock. With that in mind think of it this way. Which of these two share structures would benefit PSID and shareholders most if the company was awarded a contract?
With the current share structure a return to the 52 week high would mean a pps of .14 vs. a pps of $3.48 (1/25). A return to the 2 year high would mean a pps of $1.09 vs a pps of $27.25 (1/25).
There is no question that this R/S announcement can create short term volatility (assuming there is no further announcement/clarification from the company) however I can clearly see the potential benefit to the company and the shareholders.
Additionally the most explosive companies typically have small floats, low market caps, and low dollar per share prices similar to what would exist assuming a 1/25 spit was enacted.
All IMO of course.
Board of Advisors
Yuval Rabin
Yuval Rabin is Managing Partner at Oris Investments and brings on board deep business experience with governments, state and federal processes, and an extensive network and contacts around the globe, including Africa, Arab countries, and Eastern European countries. Rabin lives in Israel, where the Company is currently developing its Easy Check(tm) non-invasive breath glucose detection device. Rabin, son of the late Israeli Prime Minister Yitzhak Rabin, was previously a Managing Partner at the Washington, D.C.-based Rabin, Sheves, Lipkin-Shahak, and Birger ("RSLB"), and was one of the first non-Americans to lobby the U.S. administration on behalf of foreign countries. Prior to RSLB, Rabin held senior executive positions serving companies including AARP, The Principal Group, Ericsson, Airbus Industries, Nokia and Samsung among others. Rabin has also led initiatives for manufacturing and service companies, utilities and governments in the U.S., Israel, Europe and the Far East. Rabin is a veteran of the Israel Defense Forces, having achieved the rank of major during his eight years of service.
Board of Advisors
Pietro Galassetti, MD, PhD
Dr. Galassetti is Associate Professor of Pediatrics and Pharmacology at the University of California, Irvine ("UCI"), where he also serves as the Director of the Bionutrition/Metabolism Core at the Institute for Clinical and Translational Science, and as Associate Director of the Pediatric Exercise Research Center. In his role as scientific advisor to PositiveID, Galassetti will contribute his expertise on breath analysis to the development of PositiveID's Easy Check(tm) non-invasive breath glucose detection device. Galassetti has focused on developing a novel technology to measure non-invasively a broad range of metabolic variables through exhaled breath analysis, in collaboration with the UCI department of chemistry. A number of previously unstudied gases present in human breath at extremely low concentrations correlated with several key metabolic indicators, including plasma glucose, insulin, lipids, ketones and inflammatory markers, promise the near-future evolution of these measurements into clinically applicable devices. The recipient of several scientific national awards, Galassetti is a member of the editorial board of the Journal of Applied Physiology, acts as a reviewer for about 20 scientific journals, and as a grant reviewer for the NIH, the Juvenile Diabetes Foundation and several international scientific foundations.
Board of Advisors
Kimothy Smith, Ph.D., Chief Technology Advisor to MicroFluidic Systems
As current Chief Technology Advisor at PositiveID's Microfluidic Systems, Dr. Kimothy Smith provides professional consulting services in the areas of biosurveillance, bioforensics, biodefense, biosecurity, molecular genetics and diagnostics, and food safety, defense and security. Recently he was as a Senior Scientist for the Tahoe Research Initiative LLC, where he worked internationally on Global Biosurveillance issues to build capacity and capability of public and veterinary health systems. He also served as Director of The Global Resource Initiative, a nonprofit organization that focuses its efforts on bolstering the critical resource base of underserved countries and promoting sustainable agricultural practices. He was promoted to Senior Advisor for International Biodefense for the Department of Homeland Security, Office of Health Affairs and was detailed to the U.S. State Department Office of International Health and Biodefense. Prior to this he served as the Acting Director of the National Biosurveillance Integration Center, where he was responsible for setting the vision and strategy of a U.S. government-wide effort to acquire, aggregate, integrate, analyze, interpret and disseminate all-source biosurveillance information from governmental and private sectors for epidemiological analyses and health protection. Moreover, he was the Department of Homeland Security's first Chief Veterinarian and served as the Chief Scientist for the Office of Health Affairs. Dr. Smith began working for the Department of Homeland Security (DHS) in 2005 where he worked within the Science and Technology Directorate as the Chief of the Research Programs and Countermeasures Office, directing the intramural research program executed through the federal and National Laboratories. Prior to working with DHS, he was at Lawrence Livermore National Laboratory (LLNL) where he served as the Deputy Division Leader for Operations in the Counter-terrorism and Incident Response Division of the Non-proliferation, Arms Control and International Security Directorate. In this capacity Dr. Smith was responsible for maintenance and readiness of the laboratory's nuclear response deployment and assessment teams. Before accepting this appointment, Dr. Smith served as a Deputy Associate Program Leader for the Chemical and Biological National Security Program where he was responsible for administering and managing the portfolio of biodefense research projects at LLNL. He was actively engaged in research execution and program development in the areas of infectious disease ecology, developing molecular typing methods and the application of molecular epidemiological techniques to forensic investigations as an associate professor on the Northern Arizona University (NAU) faculty prior to going to LLNL. He has earned his PhD in molecular epidemiology from Louisiana State University (1999) where he curated the worldwide Bacillus anthraces collection. He earned his BS in Biochemistry and Doctorate of Veterinary Medicine from Oklahoma State University and was a practicing veterinarian for almost 10 years.
Thanks. Much appreciate the explanation.
Could DHS delay 'parts' of the BioWatch program due to sequester but not delay entire program?
For example could they delay the SETA portion due to spending cuts but move forward with biodetection systems selection?
Any thoughts?
Systems Engineering and Technical Assistance (SETA)
Congrats!
Wish I was in your shoes.
Im long since election day & SAIC news.
Chart looks better that any on my watchlist.
GLTA.
Thanks,
IMO this is all that matters & is clearly why PSID is holding on to Easy Check:
The Easy Check breath glucose test is a non-invasive glucose detection system that measures acetone levels in a patient's exhaled breath.
This could eliminate a patient's need to prick his or her finger multiple times per day to get a blood sugar reading.
Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial S
PositiveID's Easy Check breath glucose detection device and associated intellectual property is not included in the Agreement and remains the property of PositiveID.
http://biz.yahoo.com/e/130221/psid8-k.html
Mexico: Bird flu outbreak hits 582,000 chickens
Mexico's animal health agency says a bird flu outbreak at seven farms in central Mexico has affected as many as 582,000 chickens.
http://hosted.ap.org/dynamic/stories/L/LT_MEXICO_BIRD_FLU?SITE=AP&SECTION=HOME&TEMPLATE=DEFAULT&CTIME=2013-02-15-20-30-00
Thanks so much for the info!
I have found myself trading more OTC stocks the past few years but have been flying blind with no level 2.
I use TC2000 and place my orders through Scottrade due to low commissions.
I am looking to avoid paying for a third service simply for OTC level 2 and etrade pro sounds like a great option.
Does etrade offer level 2 for OTCBB stocks?
Thanks for your assistance?
Perhaps an email to PSID investor relations might help?
Dont hear much from our govt. about threat of bio attack so certainly interesting.
Probably just normal precaution however I do not believe our govt. can be trusted to tell us the truth about any real threat.
STATE OF UNION reporters watch video 'how to escape in case there is biological attack'
Not kidding: press gallery staff now showing reporters a video on how to escape tonight in case there is a biological attack #SOTU
— Jonathan Tamari (@JonathanTamari) February 13, 2013
Thanks. Just want to do my part. Lots of good info on this board.
Equipment made by PSID can test for bird flu
http://www.smallcapnetwork.com/PositiveID-Corporation-OTC-PSID-Puts-Another-Feather-In-Its-Diagnostic-Cap/s/via/1789/article/view/p/mid/3/id/116/
Two infected with bird flu in southwest China
http://www.reuters.com/article/2013/02/10/us-china-health-birdflu-idUSBRE91906T20130210
PositiveID Corporation (OTC:PSID) Puts Another Feather In Its Diagnostic Cap
PositiveID Corporation (OTC:PSID) just put another item on the menu. The diagnostic equipment maker was already packing some punch with its real-time point-of-care tests for HPV, E-coli, staph infection (the drug-resistant one), as well as a handful of other ailments. Per today's announcement though, the equipment made by PSID can also test for bird flu, which contrary to popular belief never really went away.
http://www.smallcapnetwork.com/PositiveID-Corporation-OTC-PSID-Puts-Another-Feather-In-Its-Diagnostic-Cap/s/via/1789/article/view/p/mid/3/id/116/
I agree with your sentiment.
This is not a daytrader's stock as someone here pointed out.
This news was already know to some extent so not really a catalyst to spark a big up move.
In any event, today's action shows the potential of this stock to move quickly.
These are great prices at which to accumulate.
Patience is key here IMO.
GLTA.
Stock has bottomed with stop below .04 (which is unfortunately a large spread from current pps not uncommon in pennies).
If downtrendline resistance at .06-.062 is penetrated stock should move to .08-.10 short term. Longer term move will require earnings validation.
Significant selling pressure overhang may have been allevited meaning strong up move possible with good catalyst.
All IMO of course.
GLTA.
Reversal confirmed.
Bottom is in.
GLTA.